-
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 Posted on by TrueParallel in News&Uncategorized
-
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024 Posted on by TrueParallel in News&Uncategorized
-
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies Posted on by TrueParallel in News&Uncategorized
-
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease Posted on by TrueParallel in News&Uncategorized
-
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial Posted on by TrueParallel in News&Uncategorized
-
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 Posted on by TrueParallel in News&Uncategorized
-
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure Posted on by TrueParallel in News&Uncategorized
-
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease Posted on by TrueParallel in News&Uncategorized
-
AskBio Names Mansuo Shannon Chief Scientific Officer Posted on by TrueParallel in News
-
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure Posted on by TrueParallel in News&Uncategorized
